Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET

Company Participants

Sara Pellegrino - VP, IR & Public Relations

Frederick Vogt - Interim CEO, President, General Counsel & Corporate

Raj Puri - EVP, Regulatory Strategy and Translational Medicine

James Ziegler - EVP, Commercial

Jean-Marc Bellemin - CFO, Principal Accounting Officer & Treasurer Secretary

Friedrich Finckenstein - Chief Medical Officer

Igor Bilinsky - COO

Conference Call Participants

Peter Lawson - Barclays Bank

Colleen Kusy - Robert W. Baird & Co.

Yanan Zhu - Wells Fargo Securities

Dina Elmonshed - Jefferies

Benjamin Burnett - Stifel, Nicolaus & Company

Kelsey Goodwin - Guggenheim Securities

Mara Goldstein - Mizuho Securities

Reni Benjamin - JMP Securities

Karina Rabayeva - Truist Securities

Operator

Welcome to the Iovance Biotherapeutics Third Quarter and Year-to-Date 2023 Financial Results and Corporate Update Conference Call. My name is Abigail, and I will be your operator for today's call. [Operator Instructions].

I will now turn the call over to Sara Pellegrino, Senior Vice President, Investor Relations and Corporate Communications at Iovance. Sarah, you may begin.

Sara Pellegrino

Thank you, Operator. Good afternoon, and thank you for joining us. Speaking on today's call, we have Dr. Fred Vogt, our Interim President and Chief Executive Officer; Dr. Igor Bilinsky, our Chief Operating Officer; Jim Ziegler, Executive Vice President, Commercial; Dr. Friedrich Finckenstein, our Chief Medical Officer; and Jean-Marc Bellemin, our Chief Financial Officer; Dr. Brian Gastman, Executive Vice President, Medical Affairs; and Dr. Raj Puri, our Executive Vice President, Regulatory Strategy and Translational Medicine are available for the Q&A session.

This afternoon, we issued a press release that can be found on our corporate website at iovance.com, which includes the financial results for the 3 and 9 months ended on September 30, 2023, as well as recent corporate updates.

Before we start, I would like to remind everyone that statements made during this conference call will include forward-looking statements regarding Iovance's goals, business focus, business plans and transactions, revenue, pre-commercial activities, clinical trials and results regulatory interactions, plans and strategies, research and preclinical activities, potential future applications of our technologies, manufacturing capabilities, regulatory feedback and guidance, payer interactions, licenses and collaboration, cash position and expense guidance and future updates.

Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond our control, including the risks and uncertainties described from time to time in our SEC filings. Our results may differ materially from those projected during today's call. We undertake no obligation to publicly update any forward-looking statements.